The cardioprotective effects of CGRP (10), including the (1) antihypertensive effects, (2) attenuating cardiac remodeling, and (3) increasing angiogenesis to limit damage associated with the progression of cardiovascular diseases, raises concerns regarding long-term blockade of CGRP in individuals with migraine who are at high risk for ischaemic events or have a history of a myocardial infarction, coronary artery disease, and cerebrovascular accidents. The gene discussed is CALCA; the disease is migraine disorder.